Literature DB >> 7562281

Anti-pneumococcal antibody levels three to seven years after first booster immunization in children with sickle cell disease, and after a second booster.

S P Rao1, K Rajkumar, G Schiffman, N Desai, C Unger, S T Miller.   

Abstract

We measured pneumococcal antibody levels in 55 patients (ages 7 to 20 years) with sickle cell disease 3 to 7 years after the first booster immunization. Only 6 of the children had protective levels of antibodies (> 300 ng/ml) against all 12 serotypes tested. Thirty-two children (58%) had suboptimal levels against 1 to 3 serotypes; 17 had suboptimal levels against 4 to 10 serotypes. Ten patients from the latter group (ages 13 to 17 years) received a second booster 6 to 8 years after the first booster immunization, and had a marked increase in antibody levels against all serotypes with the exception of serotypes 3 and 4 in two patients and serotype 6A in one patient.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7562281     DOI: 10.1016/s0022-3476(95)70119-2

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  6 in total

1.  Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs.

Authors:  B G Harvey; N R Hackett; T El-Sawy; T K Rosengart; E A Hirschowitz; M D Lieberman; M L Lesser; R G Crystal
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

Review 2.  Use of licensed vaccines for active immunization of the immunocompromised host.

Authors:  L A Pirofski; A Casadevall
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

Review 3.  Advances in pneumococcal vaccines: advantages for infants and children.

Authors:  Jolanta Bernatoniene; Adam Finn
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Assessing the Immunogenic Response of a Single Center's Pneumococcal Vaccination Protocol in Sickle Cell Disease.

Authors:  Jonathan D Santoro; Leann Myers; Julie Kanter
Journal:  J Pediatr Hematol Oncol       Date:  2016-04       Impact factor: 1.289

5.  Poor Long-Term Efficacy of Prevnar-13 in Sickle Cell Disease Mice Is Associated with an Inability to Sustain Pneumococcal-Specific Antibody Titers.

Authors:  Steven M Szczepanek; Sean Roberts; Kara Rogers; Christina Cotte; Alexander J Adami; Sonali J Bracken; Sharon Salmon; Eric R Secor; Roger S Thrall; Biree Andemariam; Dennis W Metzger
Journal:  PLoS One       Date:  2016-02-24       Impact factor: 3.240

6.  Maintenance of an Immunogenic Response to Pneumococcal Vaccination in Children With Sickle Cell Disease.

Authors:  Mahvish Q Rahim; Alexandria M Arends; Seethal A Jacob
Journal:  J Pediatr Hematol Oncol       Date:  2022-01-01       Impact factor: 1.289

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.